Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

Purpose Of Review: To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response.

Recent Findings: Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognostic models that predict disease course have therefore been developed.

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy.

Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10⁻20% of patients with early stage disease and 30⁻40% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolidation with high dose therapy and autologous stem cell transplant (ASCT). Patients who achieve a complete response to salvage therapy prior to ASCT have better outcomes, thus recent studies have focused on incorporating newer agents in this setting.